Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Total Current Liabilities (2021 - 2025)

Stoke Therapeutics has reported Total Current Liabilities over the past 5 years, most recently at $57.9 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 44.49% year-over-year to $57.9 million; the TTM value through Dec 2025 reached $57.9 million, up 44.49%, while the annual FY2025 figure was $57.9 million, 44.49% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $57.9 million at Stoke Therapeutics, up from $41.7 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $57.9 million in Q4 2025 and troughed at $17.1 million in Q4 2021.
  • A 5-year average of $34.7 million and a median of $31.5 million in 2023 define the central range for Total Current Liabilities.
  • Biggest five-year swings in Total Current Liabilities: dropped 21.02% in 2023 and later soared 103.76% in 2024.
  • Year by year, Total Current Liabilities stood at $17.1 million in 2021, then soared by 83.17% to $31.4 million in 2022, then fell by 1.83% to $30.8 million in 2023, then grew by 29.97% to $40.1 million in 2024, then soared by 44.49% to $57.9 million in 2025.
  • Business Quant data shows Total Current Liabilities for STOK at $57.9 million in Q4 2025, $41.7 million in Q3 2025, and $38.7 million in Q2 2025.